Abstract

The major function of the Protocol Review and Monitoring System (PRMS) is to provide a mechanism for scientific review and research oversight of all UWCCC clinical research trials. The Cancer Center has charged this oversight responsibility to two committees, the Clinical Affairs Committee (CAC) and Clinical Trials Monitoring Committee (CTMC). The CAC performs review of all new research relative to its scientific merit and priority within the UWCCC. The relationship between the CAC and the University of Wisconsin Human Subjects Committee (HSC) remains strong and complementary. The HSC relies heavily on CAC scientific review and, in its formal policy, continues to support CAC authority to active, disapprove, or terminate UWCCC trials. The CTMC monitors the progress of all ongoing clinical trials reporting their findings to the CAC. An additional PRCS activity involves the monitoring oversight of cancer control/non-treatment trials, the review of all quality control and safety reports. These two committees report to UWCCC senior leadership of cancer control/non-treatment trials, the review of all quality control and safety reports. These two committees report to UWCCC senior leadership through the Clinical Research Committee (CRC) for all their activities.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-30
Application #
6581168
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-04-01
Project End
2003-03-31
Budget Start
Budget End
Support Year
30
Fiscal Year
2002
Total Cost
Indirect Cost

  Institution

Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715

  Publications

Ni, Dalong; Jiang, Dawei; Kutyreff, Christopher J et al. (2018) Molybdenum-based nanoclusters act as antioxidants and ameliorate acute kidney injury in mice. Nat Commun 9:5421
Huynh, Mailee; Pak, Chorom; Markovina, Stephanie et al. (2018) Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-?B activity and increases drug resistance in multiple myeloma. J Biol Chem 293:2452-2465
Wu, Yirong; Fan, Jun; Peissig, Peggy et al. (2018) Quantifying predictive capability of electronic health records for the most harmful breast cancer. Proc SPIE Int Soc Opt Eng 10577:
Fu, Anqi; Oberholtzer, Sydney M; Bagheri-Fam, Stefan et al. (2018) Dynamic expression patterns of Irx3 and Irx5 during germline nest breakdown and primordial follicle formation promote follicle survival in mouse ovaries. PLoS Genet 14:e1007488
Jiang, Dawei; Ge, Zhilei; Im, Hyung-Jun et al. (2018) DNA origami nanostructures can exhibit preferential renal uptake and alleviate acute kidney injury. Nat Biomed Eng 2:865-877
Seok, Seung-Hyeon; Ma, Zhi-Xiong; Feltenberger, John B et al. (2018) Trace derivatives of kynurenine potently activate the aryl hydrocarbon receptor (AHR). J Biol Chem 293:1994-2005
Farrell, Emily; Armstrong, Annie E; Grimes, Adrian C et al. (2018) Transcriptome Analysis of Cardiac Hypertrophic Growth in MYBPC3-Null Mice Suggests Early Responders in Hypertrophic Remodeling. Front Physiol 9:1442
Net, Jose M; Whitman, Gary J; Morris, Elizabteh et al. (2018) Relationships Between Human-Extracted MRI Tumor Phenotypes of Breast Cancer and Clinical Prognostic Indicators Including Receptor Status and Molecular Subtype. Curr Probl Diagn Radiol :
Guerrero, Natalie; Small, Alissa L; Schwei, Rebecca J et al. (2018) Informing physician strategies to overcome language barriers in encounters with pediatric patients. Patient Educ Couns 101:653-658
Chapelin, Fanny; Capitini, Christian M; Ahrens, Eric T (2018) Fluorine-19 MRI for detection and quantification of immune cell therapy for cancer. J Immunother Cancer 6:105

Showing the most recent 10 out of 1528 publications